His scientific interests lie mostly in RNA, Oligonucleotide, Biochemistry, RNase P and RNase H. His study looks at the intersection of RNA and topics like Cell biology with Gene expression and Messenger RNA. His work on Antisense oligonucleotides as part of general Oligonucleotide study is frequently connected to Mechanism, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His work on Nuclease, Enzyme, Binding site and Binding selectivity as part of general Biochemistry study is frequently linked to Ribostamycin, therefore connecting diverse disciplines of science. His research on RNase P frequently links to adjacent areas such as Molecular biology. His RNase H study integrates concerns from other disciplines, such as Cleavage and RNase MRP.
His primary areas of investigation include Oligonucleotide, RNA, Molecular biology, Biochemistry and RNase P. His research investigates the connection with Oligonucleotide and areas like Computational biology which intersect with concerns in Drug discovery. His studies in RNA integrate themes in fields like Gene silencing and Function, Cell biology.
The Molecular biology study combines topics in areas such as RNA-induced silencing complex, Small interfering RNA, Messenger RNA, Gene and Nuclease protection assay. His RNase P study combines topics in areas such as Cleavage and DNA. As a part of the same scientific study, Stanley T. Crooke usually deals with the Antisense oligonucleotides, concentrating on Pharmacology and frequently concerns with Apolipoprotein B.
Stanley T. Crooke mostly deals with Oligonucleotide, Cell biology, RNA, RNase P and Molecular biology. His Oligonucleotide study is related to the wider topic of Biochemistry. His Cell biology study incorporates themes from Cell and RNA splicing.
His biological study spans a wide range of topics, including Regulation of gene expression, Computational biology, Gene expression and Recombinant DNA. His work deals with themes such as Locked nucleic acid, Messenger RNA, Transcription and Antisense Technology, which intersect with RNase P. Stanley T. Crooke combines subjects such as Cytoplasm, Exosome complex, Small interfering RNA, RNA silencing and RNase MRP with his study of Molecular biology.
Stanley T. Crooke mainly focuses on RNA, Oligonucleotide, RNase P, Molecular biology and Cell biology. His research in RNA intersects with topics in Gene silencing and Gene expression. Oligonucleotide is a primary field of his research addressed under Biochemistry.
His work in the fields of Biochemistry, such as Phosphorothioate Oligonucleotides and Nuclease, intersects with other areas such as Endocytosis Pathway. His RNase P research includes themes of Locked nucleic acid, Cytoplasm and Messenger RNA. His work in Cell biology covers topics such as Paraspeckle which are related to areas like Small nuclear RNA, RNA silencing and Non-coding RNA.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Frederick J Raal;Raul D Santos;Dirk J Blom;A David Marais.
The Lancet (2010)
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents: A COMPARATIVE ANALYSIS *
Timothy A. Vickers;Seongjoon Koo;C. Frank Bennett;Stanley T. Crooke.
Journal of Biological Chemistry (2003)
Oligoribonucleotides and ribonucleases for cleaving RNA
Stanley T. Crooke.
(1997)
Progress in Antisense Technology
Stanley T. Crooke.
Annual Review of Medicine (2004)
Molecular mechanisms of action of antisense drugs.
Stanley T Crooke.
Biochimica et Biophysica Acta (1999)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J Viney;Julian C van Capelleveen;Richard S Geary;Shuting Xia.
The Lancet (2016)
Oligoribonucleotides for cleaving RNA
Stanley T. Crooke.
(1996)
Therapeutic applications of oligonucleotides.
Stanley T. Crooke.
Annual Review of Pharmacology and Toxicology (1992)
Progress in antisense oligonucleotide therapeutics.
S T Crooke;C F Bennett.
Annual Review of Pharmacology and Toxicology (1996)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham;Kristina M. Lemonidis;Charles P. Whipple;Amuthakannan Subramaniam.
Journal of Lipid Research (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Ionis Pharmaceuticals (United States)
Ionis Pharmaceuticals (United States)
Ionis Pharmaceuticals (United States)
Ionis Pharmaceuticals (United States)
Ionis Pharmaceuticals (United States)
Ionis Pharmaceuticals (United States)
University of California, San Diego
Ionis Pharmaceuticals (United States)
Alnylam Pharmaceuticals (United States)
University of California, San Diego
University of California, Santa Cruz
University of Hong Kong
Georgia Institute of Technology
University of Leoben
Chinese Academy of Sciences
Colorado School of Mines
Purdue University West Lafayette
INRAE : Institut national de recherche pour l'agriculture, l'alimentation et l'environnement
Imperial College London
The University of Texas Southwestern Medical Center
Medical University of South Carolina
University of California, San Diego
Harvard University
University of Haifa
Central European University
Liverpool John Moores University